Cargando…
Prescribing pre-exposure prophylaxis for HIV
Co-formulated tenofovir disoproxil plus emtricitabine is highly effective as pre-exposure prophylaxis for HIV It is suitable for men who have sex with men, for heterosexual sex and for people who use intravenous drugs when there is a risk of HIV infection Pre-exposure prophylaxis is one pill per day...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
NPS MedicineWise
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738695/ https://www.ncbi.nlm.nih.gov/pubmed/33363302 http://dx.doi.org/10.18773/austprescr.2020.057 |
_version_ | 1783623174721634304 |
---|---|
author | Bloch, Mark |
author_facet | Bloch, Mark |
author_sort | Bloch, Mark |
collection | PubMed |
description | Co-formulated tenofovir disoproxil plus emtricitabine is highly effective as pre-exposure prophylaxis for HIV It is suitable for men who have sex with men, for heterosexual sex and for people who use intravenous drugs when there is a risk of HIV infection Pre-exposure prophylaxis is one pill per day and can be prescribed by all medical practitioners and nurse practitioners via the Pharmaceutical Benefits Scheme. It is best prescribed in a three-monthly program with regular monitoring for patient adherence, safety, HIV and other sexually transmitted infections Prophylaxis is well tolerated but requires monitoring for kidney toxicity and low bone density |
format | Online Article Text |
id | pubmed-7738695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | NPS MedicineWise |
record_format | MEDLINE/PubMed |
spelling | pubmed-77386952020-12-23 Prescribing pre-exposure prophylaxis for HIV Bloch, Mark Aust Prescr Article Co-formulated tenofovir disoproxil plus emtricitabine is highly effective as pre-exposure prophylaxis for HIV It is suitable for men who have sex with men, for heterosexual sex and for people who use intravenous drugs when there is a risk of HIV infection Pre-exposure prophylaxis is one pill per day and can be prescribed by all medical practitioners and nurse practitioners via the Pharmaceutical Benefits Scheme. It is best prescribed in a three-monthly program with regular monitoring for patient adherence, safety, HIV and other sexually transmitted infections Prophylaxis is well tolerated but requires monitoring for kidney toxicity and low bone density NPS MedicineWise 2020-12-01 2020-12 /pmc/articles/PMC7738695/ /pubmed/33363302 http://dx.doi.org/10.18773/austprescr.2020.057 Text en (c) NPS MedicineWise http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License. |
spellingShingle | Article Bloch, Mark Prescribing pre-exposure prophylaxis for HIV |
title | Prescribing pre-exposure prophylaxis for HIV |
title_full | Prescribing pre-exposure prophylaxis for HIV |
title_fullStr | Prescribing pre-exposure prophylaxis for HIV |
title_full_unstemmed | Prescribing pre-exposure prophylaxis for HIV |
title_short | Prescribing pre-exposure prophylaxis for HIV |
title_sort | prescribing pre-exposure prophylaxis for hiv |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738695/ https://www.ncbi.nlm.nih.gov/pubmed/33363302 http://dx.doi.org/10.18773/austprescr.2020.057 |
work_keys_str_mv | AT blochmark prescribingpreexposureprophylaxisforhiv |